{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T15:02:56Z","timestamp":1787065376774,"version":"build-2736575974"},"reference-count":39,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2005,10,1]],"date-time":"2005-10-01T00:00:00Z","timestamp":1128124800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2005,10]]},"DOI":"10.1016\/j.clinthera.2005.10.009","type":"journal-article","created":{"date-parts":[[2005,12,5]],"date-time":"2005-12-05T07:37:06Z","timestamp":1133768226000},"page":"1500-1512","source":"Crossref","is-referenced-by-count":140,"title":["Pramlintide in the treatment of type 1 and type 2 diabetes mellitus"],"prefix":"10.1016","volume":"27","author":[{"given":"Gina J.","family":"Ryan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lynetta J.","family":"Jobe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rhonda","family":"Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2005.10.009_bib1","doi-asserted-by":"crossref","first-page":"1936","DOI":"10.2337\/diacare.24.11.1936","article-title":"Projection of diabetes burden through 2050: The impact of changing demography and disease prevalence in the US","volume":"24","author":"Boyle","year":"2001","journal-title":"Diabetes Care"},{"key":"10.1016\/j.clinthera.2005.10.009_bib2","doi-asserted-by":"crossref","first-page":"149","DOI":"10.2165\/00019053-200422030-00002","article-title":"Cost-of-illness studies in diabetes mellitus","volume":"22","author":"Ettaro","year":"2004","journal-title":"Pharmacoeconomics"},{"issue":"Suppl 1","key":"10.1016\/j.clinthera.2005.10.009_bib3","first-page":"537","article-title":"Diagnosis and classification of diabetes mellitus","volume":"28","author":"American Diabetes Association","year":"2005","journal-title":"Diabetes Care"},{"key":"10.1016\/j.clinthera.2005.10.009_bib4","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1056\/NEJM199309303291401","article-title":"The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus","volume":"329","year":"1993","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2005.10.009_bib5","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1016\/S0140-6736(98)07037-8","article-title":"Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34)","volume":"352","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/j.clinthera.2005.10.009_bib6","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/S0140-6736(98)07019-6","article-title":"Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type2 diabetes (UKPDS 33)","volume":"352","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/j.clinthera.2005.10.009_bib7","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1001\/jama.291.3.335","article-title":"Poor control of risk factors for vascular disease among adults with previously diagnosed diabetes","volume":"291","author":"Saydah","year":"2004","journal-title":"JAMA"},{"key":"10.1016\/j.clinthera.2005.10.009_bib8","first-page":"8628","article-title":"Purification and characterization of a peptide from amyloid-rich pancreases of type 2 diabetic patients","volume":"84","author":"Cooper","year":"1987"},{"key":"10.1016\/j.clinthera.2005.10.009_bib9","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1016\/0140-6736(92)90785-2","article-title":"Amylin concentrations and glucose control","volume":"339","author":"Koda","year":"1992","journal-title":"Lancet"},{"key":"10.1016\/j.clinthera.2005.10.009_bib10","first-page":"493","article-title":"High affinity amylin binding sites in rat brain","volume":"44","author":"Beaumont","year":"1993","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.clinthera.2005.10.009_bib11","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/0306-4522(94)90388-3","article-title":"In vitro autoradiographic localization of amylin binding sites in rat brain","volume":"62","author":"Sexton","year":"1994","journal-title":"Neuroscience"},{"key":"10.1016\/j.clinthera.2005.10.009_bib12","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1113\/jphysiol.2004.072736","article-title":"Prolactin-releasing peptide affects gastric motor function in rat by modulating synaptic transmission in the dorsal vagal complex","volume":"561","author":"Grabauska","year":"2004","journal-title":"J Physiol"},{"key":"10.1016\/j.clinthera.2005.10.009_bib13","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1038\/sj.ijo.0801664","article-title":"The anorectic effect of a chronic peripheral infusion of amylin is abol ished in area postrema\/nucleus of solitary tract (AP\/NTS) lesioned rats","volume":"25","author":"Lutz","year":"2001","journal-title":"Int J Obes Relat Metab Disord"},{"key":"10.1016\/j.clinthera.2005.10.009_bib14","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1210\/en.141.1.406","article-title":"Coexpression of receptors for adrenomedullin, calcitonin gene related peptide, and amylin in pancreatic beta-cells","volume":"141","author":"Martinez","year":"2000","journal-title":"Endocrinologl"},{"key":"10.1016\/j.clinthera.2005.10.009_bib15","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.2174\/1381612013397357","article-title":"Amylin replacement with pramlintide as an adjunct to insulin therapy in type 1 and type 2 diabetes mellitus: A physiological approach toward improved metabolic control","volume":"7","author":"Weyer","year":"2001","journal-title":"Curr Pharm Des"},{"key":"10.1016\/j.clinthera.2005.10.009_bib16","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1002\/jcb.240550004","article-title":"Molecular physiology of amylin","volume":"55","author":"Pittner","year":"1994","journal-title":"J Cell Biochem"},{"key":"10.1016\/j.clinthera.2005.10.009_bib17","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1055\/s-2002-34790","article-title":"The human amylin analog, pramlintide, reduces postprandial hyper glucagonemia in patients with type 2 diabetes mellitus","volume":"34","author":"Fineman","year":"2002","journal-title":"Horm Metab Res"},{"key":"10.1016\/j.clinthera.2005.10.009_bib18","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1007\/s001250050646","article-title":"Infusion of pramlintide, a human amylin analogue, delays gastric emptying in men with IDDM","volume":"40","author":"Kong","year":"1997","journal-title":"Diabetologia"},{"key":"10.1016\/j.clinthera.2005.10.009_bib19","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1007\/s001250050949","article-title":"The effect of single doses of pramlintide on gastric emptying of two meals in men with IDDM","volume":"41","author":"Kong","year":"1998","journal-title":"Diabetologia"},{"key":"10.1016\/j.clinthera.2005.10.009_bib20","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1002\/dmrr.419","article-title":"Pramlintide reduces postprandial glucose excursions when added to insulin lispro in subjects with type 2 diabetes: A dose-timing study","volume":"20","author":"Maggs","year":"2004","journal-title":"Diabetes Metab Res Rev"},{"key":"10.1016\/j.clinthera.2005.10.009_bib21","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1002\/(SICI)1096-9136(199707)14:7<547::AID-DIA390>3.0.CO;2-U","article-title":"Pramlintide: A human amylin analogue reduced postprandial plas ma glucose, insulin, and C-peptide concentrations in patients with type 2 diabetes","volume":"14","author":"Thompson","year":"1997","journal-title":"Diabet Med"},{"key":"10.1016\/j.clinthera.2005.10.009_bib22","doi-asserted-by":"crossref","first-page":"632","DOI":"10.2337\/diabetes.46.4.632","article-title":"Effects of pramlintide, an analog of human amylin, on plasma glucose profiles in patients with IDDM: Results of a multicenter trial","volume":"46","author":"Thompson","year":"1997","journal-title":"Diabetes"},{"key":"10.1016\/j.clinthera.2005.10.009_bib23","doi-asserted-by":"crossref","first-page":"3074","DOI":"10.2337\/diacare.26.11.3074","article-title":"Pramlintide reduces postprandial glucose excursions when added to regular insulin or insulin lispro in subjects with type 1 diabetes: A closetimingstudy","volume":"26","author":"Weyer","year":"2003","journal-title":"Diabetes Care"},{"key":"10.1016\/j.clinthera.2005.10.009_bib24","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2337\/diacare.26.1.1","article-title":"Impact of pramlintide on glucose fluctuations and postprandial glu cose, glucagon, and triglyceride excursions among patients with type 1 diabetes intensively treated with insulin pumps","volume":"26","author":"Levetan","year":"2003","journal-title":"Diabetes Care"},{"key":"10.1016\/j.clinthera.2005.10.009_bib25","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1016\/S0026-0495(99)90232-9","article-title":"The amylin analog pramlintide improves glycemic control and reduces postprandial glucagon concentrations in patients with type 1 diabetes mellitus","volume":"48","author":"Nyholm","year":"1999","journal-title":"Metabolism"},{"key":"10.1016\/j.clinthera.2005.10.009_bib26","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1046\/j.1365-2982.2002.00311.x","article-title":"Effects of pramlintide, an amylin analogue, on gastric emptying in type 1 and 2 diabetes mellitus","volume":"14","author":"Vella","year":"2002","journal-title":"Neurogastroenterol Motil"},{"key":"10.1016\/j.clinthera.2005.10.009_bib27","series-title":"Symlin [package insert]","year":"2005"},{"key":"10.1016\/j.clinthera.2005.10.009_bib28","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1007\/s001250050821","article-title":"Effects of 4 weeks' administration of pramlintide, a human amylin analogue, on glycaemia control in patients with IDDM: Effects on plasma glucoseprofiles and serum fructosamine concentrations","volume":"40","author":"Thompson","year":"1997","journal-title":"Diabetologia"},{"issue":"Suppl 1","key":"10.1016\/j.clinthera.2005.10.009_bib29","first-page":"A113","article-title":"Effects of six months administration of pramlintide as an adjunct to insulin therapy on metabolic control in people with type 1 diabetes","volume":"48","author":"Fineman","year":"1999","journal-title":"Diabetes"},{"key":"10.1016\/j.clinthera.2005.10.009_bib30","doi-asserted-by":"crossref","first-page":"724","DOI":"10.2337\/diacare.25.4.724","article-title":"A randomized study and open-label extension evaluating the long-term efficacy of pramlintide as an adjunct to insulin therapy in type 1 diabetes","volume":"25","author":"Whitehouse","year":"2002","journal-title":"Diabetes Care"},{"key":"10.1016\/j.clinthera.2005.10.009_bib31","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1111\/j.1464-5491.2004.01319.x","article-title":"Amylin replacement with pramlintide as an adjunct to insulin ther apy improves long-term glycaemic and weight control in type 1 diabetes mellitus: A 1-year, randomized controlled trial","volume":"21","author":"Ratner","year":"2004","journal-title":"Diabet Med"},{"key":"10.1016\/j.clinthera.2005.10.009_bib32","doi-asserted-by":"crossref","first-page":"987","DOI":"10.2337\/diacare.21.6.987","article-title":"Pramlintide, a synthetic analog of human amylin, improves the metabolic profile of patients with type 2 diabetes using insulin","volume":"21","author":"Thompson","year":"1998","journal-title":"Diabetes Care"},{"issue":"Suppl 1","key":"10.1016\/j.clinthera.2005.10.009_bib33","first-page":"A232","article-title":"Pramlintide therapy in addition to insulin in type 2 diabetes: Effect on metabolic control after 6 months","volume":"42","author":"Gottlieb","year":"1999","journal-title":"Diabetologia"},{"key":"10.1016\/j.clinthera.2005.10.009_bib34","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1089\/15209150252924094","article-title":"Adjunctive therapy with the amylin analogue pramlintide leads to a combined improvement in glycemic and weight control in insulintreated subjectswith type 2 diabetes","volume":"4","author":"Ratner","year":"2002","journal-title":"Diabetes Technol Ther"},{"key":"10.1016\/j.clinthera.2005.10.009_bib35","doi-asserted-by":"crossref","first-page":"784","DOI":"10.2337\/diacare.26.3.784","article-title":"Pramlintide as an adjunct to insulin therapy improves long-term glycemic and weight control in patients with type 2 diabetes: A 1-year randomizedcontrolled trial","volume":"26","author":"Hollander","year":"2003","journal-title":"Diabetes Care"},{"key":"10.1016\/j.clinthera.2005.10.009_bib36","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1016\/j.metabol.2003.06.003","article-title":"Effect of pramlintide on A1C and bodyweight in insulin-treated African Americans and Hispanics with type 2 diabetes: A pooled post hoc analysis","volume":"52","author":"Maggs","year":"2003","journal-title":"Metabolism"},{"key":"10.1016\/j.clinthera.2005.10.009_bib37","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1046\/j.1463-1326.2003.00295.x","article-title":"Addition of pramlintide to insulin therapy lowers HbA1c in conjunction with weight loss in patients with type 2 diabetes approaching glycaemic targets","volume":"5","author":"Hollander","year":"2003","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.clinthera.2005.10.009_bib38","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1093\/ajhp\/62.8.816","article-title":"Properties of pramlintide and insulin upon mixing","volume":"62","author":"Weyer","year":"2005","journal-title":"Am J Health Syst Pharm"},{"issue":"Suppl 1","key":"10.1016\/j.clinthera.2005.10.009_bib39","first-page":"A232","article-title":"Pramlintide therapy in addition to insulin in type 1 diabetes: Effect on metabolic control after 6 months","volume":"42","author":"Fineman","year":"1999","journal-title":"Diabetologia"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291805001979?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291805001979?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,4,9]],"date-time":"2019-04-09T02:12:48Z","timestamp":1554775968000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291805001979"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,10]]},"references-count":39,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2005,10]]}},"alternative-id":["S0149291805001979"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2005.10.009","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2005,10]]}}}